VCM
BLFS

Versant Capital Management’s BioLife Solutions BLFS Stock Holding History

Versant Capital Management’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19.3K Hold
498
– – ﹤0.01% 1978
2026
Q2 		$14.1K Buy
498
+42
+9% +$982 ﹤0.01% 2106
2026
Q1 		$8.7K Sell
456
-370
-45% -$8.18K ﹤0.01% 2192
2025
Q4 		$20K Hold
826
– – ﹤0.01% 1642
2025
Q3 		$21.1K Sell
826
-484
-37% -$11.5K ﹤0.01% 1552
2025
Q2 		$28.2K Buy
1,310
+1,170
+836% +$26.4K ﹤0.01% 1321
2025
Q1 		$3.2K Buy
140
+44
+46% +$1.16K ﹤0.01% 2185
2024
Q4 		$2.49K Buy
96
+15
+19% +$373 ﹤0.01% 2003
2024
Q3 		$2.03K Buy
+81
New +$1.91K ﹤0.01% 1557

Other funds holding BLFS

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Versant Capital Management's BLFS Position: Q3 2026 in Review

Versant Capital Management held its BioLife Solutions (BLFS) position steady in Q3 2026 at 498 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1978.

Versant Capital Management first reported a position in BLFS in Q3 2024 and has held it in 9 quarters since. The position peaked at $28.2K in Q2 2025. 5 funds tracked by Wall St. Rank hold BLFS as of Q3 2026.

  • Versant Capital Management held 498 shares of BioLife Solutions worth $19.3K as of Q3 2026.
  • Versant Capital Management left its BioLife Solutions share count unchanged in Q3 2026.
  • BioLife Solutions made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1978 holding.
  • Versant Capital Management first reported a position in BioLife Solutions in Q3 2024 and has held it in 9 quarters since.
  • Versant Capital Management's BioLife Solutions position peaked at $28.2K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held BioLife Solutions as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.